BioXcel Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
June 05 2018 - 8:00AM
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage
biopharmaceutical development company utilizing novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology, today announced that Dr. Vimal
Mehta, Founder and Chief Executive Officer of BTI, will present at
the Jefferies 2018 Global Healthcare Conference being held June 5 –
8, 2018 in New York City.
Details of the Conference:
Event: |
|
|
Jefferies Global
Healthcare Conference |
Date: |
|
|
June 7, 2018 |
Time: |
|
|
3:00 - 3:25 PM ET |
|
|
|
|
A live webcast of the presentation will be accessible through
the Investors section of the company's website at
www.bioxceltherapeutics.com. Following the conference, the webcast
will be archived on the BioXcel Therapeutics, Inc. website for 30
days. In addition to his presentation, Dr. Mehta will be hosting
1-on-1 investor meetings at the conference. Investors attending the
conference who are interested in meeting with BTI management should
contact their Jefferies representative.
About BioXcel Therapeutics, Inc.:BioXcel
Therapeutics, Inc. is a clinical stage biopharmaceutical company
focused on drug development that utilizes novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology. BTI’s drug re-innovation approach
leverages existing approved drugs and/or clinically validated
product candidates together with big data and proprietary machine
learning algorithms to identify new therapeutic indices. BTI’s two
most advanced clinical development programs are BXCL501, a
sublingual thin film formulation designed for acute treatment of
agitation resulting from neurological and psychiatric disorders,
and BXCL701, an immuno-oncology agent designed for treatment of a
rare form of prostate cancer and for treatment of pancreatic
cancer.
Forward-Looking StatementsThis press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to BXCL701’s advancement and development,
the presentation of data at ASCO and other information that is not
historical information. When used herein, words such as
“anticipate”, “being”, “will”, “may”, “continue”, and similar
expressions are intended to identify forward-looking statements. In
addition, any statements or information that refer to expectations,
beliefs, plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon BioXcel’s current expectations and
various assumptions. BioXcel believes there is a reasonable basis
for its expectations and beliefs, but they are inherently
uncertain. BioXcel may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various factors, including, without
limitation, market conditions and the factors described under “Risk
Factors” in BioXcel’s prospectus dated March 7, 2018 and BioXcel’s
other filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as BioXcel’s current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. BioXcel
cannot guarantee future results, events, levels of activity,
performance or achievements. BioXcel does not undertake and
specifically declines any obligation to update, republish, or
revise any forward-looking statements to reflect new information,
future events or circumstances or to reflect the occurrences of
unanticipated events, except as may be required by law.
Contact Information:The Ruth GroupLee Roth/
Janhavi Mohite646-536-7012/7026lroth@theruthgroup.com/
jmohite@theruthgroup.com
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024